Project Grant R01AI176934

Award Date 5/17/24
Completion Date 3/31/29
Dollars Obligated $558K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Ithaca, NY 14853, USA
Similar Awards
This Project Grant award for $1,010,290 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the role of alveolar macrophages as potential HIV reservoirs and drivers of persistent inflammation and immune activation in people living with HIV (PLWH) on antiretroviral therapy (ART). The multi-year study, led by researchers at Emory University, will use cutting-edge technologies and...
This Project Grant award of $234,115 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to characterize the HIV latent reservoir and determine the mechanisms driving clonal proliferation of infected cells in people living with HIV on antiretroviral therapy. The key objectives are to: 1) fully characterize the clonality distribution of intact and defective HIV proviruses through deep...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $624,902 to the University of Texas Health Science Center at San Antonio (UTHSCSA) to conduct research on the impact of the HIV accessory protein VPR on epigenetic remodeling and HIV persistence in myeloid cells. The primary objectives of this 5-year award are to: 1) characterize how VPR-directed epigenetic...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $884,322 Project Grant (R01AI186721) to the Fred Hutchinson Cancer Center to study the mechanisms that create and sustain the HIV reservoir, a population of latently infected cells that persists during antiretroviral therapy (ART) and prevents a cure for HIV. The research team, led by Dr. Reeves and collaborators at The Johns Hopkins University,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $794,045 to the University of California, San Francisco (UCSF) to study mechanisms driving HIV reservoir decay and long-term viral control. The key objectives are to: Identify host cellular drivers of class II cytokine-mediated viral control across different stages of HIV infection, including acute infection, ART...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $647,800 to The Regents of the University of California, San Francisco (UCSF) from July 2024 through May 2026. The grant aims to characterize the waning antiviral activity of antiretroviral therapy (ART) and novel broadly neutralizing antibodies (bNAbs) during treatment interruption studies for people with HIV. The...
This $205,153 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of pulmonary arterial smooth muscle cells (PVSMC) as potential HIV reservoirs. The research aims to determine the ability of PVSMC to sustain chronic HIV infection and spread the virus to surrounding immune cells, even during antiretroviral therapy. Additionally, the project...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $211,950 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of California, Irvine to investigate how HIV-1 continues to drive immune activation and inflammation in people living with HIV (PLWH) despite suppression by antiretroviral therapy (ART). The research aims to test the hypothesis that immune complexes containing HIV-1 Gag protein, viral RNA, and anti-Gag antibodies...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $1,617,200 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Arizona. This 2-year award, effective from August 2024 to July 2025, will support research to investigate the immune microenvironments that impact HIV persistence and expression during antiretroviral therapy (ART). The key objectives of this research project are to: 1) determine the location,...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $500,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, titled "Modulating T Cell Activation to Combat HIV Persistence," aims to elucidate the molecular mechanisms underlying HIV-specific T cell dysfunction and viral persistence. The research will focus on three...

VIROLOGIC AND IMMUNOLOGIC IMPACTS OF ACTIVE VIRAL PERSISTENCE IN LUNG AMS OF HIV-1-INFECTED, CART-SUPPRESSED INDIVIDUALS - PROJECT SUMMARY / ABSTRACT PERSISTENCE OF HIV-1 IN TISSUE RESERVOIRS OF THERAPY-SUPPRESSED, AVIREMIC INDIVIDUALS IS A MAJOR CHALLENGE TO HIV-1 CURE. THE VIRAL RESERVOIR CONSISTS OF MYELOID AND LYMPHOID CELLS THAT HARBOR THE VIRUS THROUGH LONG PERIODS OF COMBINATION ANTI-RETROVIRAL THERAPY (CART). UNTIL RECENTLY, IT WAS THOUGHT THAT HIV-1 PROVIRUS REMAINS IN A TRANSCRIPTIONALLY-SILENT, LATENT STATE IN THESE RESERVOIR CELLS AND ONLY RESUMES VIRAL TRANSCRIPTION AND VIRION PRODUCTION UPON ACTIVATION FROM ENDOGENOUS OR EXOGENOUS STIMULI. HOWEVER, IT IS NOW EVIDENT THAT IN A SUBSET OF RESERVOIR CELLS, THE VIRUS REMAINS TRANSCRIPTIONALLY-ACTIVE EVEN UNDER CART AND CONTINUES TO GENERATE SOME LEVELS OF VIRAL RNAS AND/OR PROTEINS. EVEN IN ABSENCE OF COMPLETE VIRAL REPLICATION, PERSISTENT VIRAL RNA AND PROTEIN PRODUCTION IN THESE "ACTIVE" RESERVOIRS POSE SIGNIFICANT ADVERSE IMMUNOLOGIC AND VIROLOGIC CONSEQUENCES. THEY CAN CONTRIBUTE TO THE CHRONIC IMMUNE ACTIVATION AS WELL AS IMPACT VIRAL REBOUND UPON TREATMENT INTERRUPTION. ALONG WITH THE TRANSCRIPTIONALLY-SILENT, LATENTLY-INFECTED CELLS, ELIMINATION OF THESE VIRAL TRANSCRIPTIONALLY-ACTIVE RESERVOIRS WOULD BE NECESSARY TO ACHIEVE A CURE FOR HIV-1. MOST OF OUR CURRENT KNOWLEDGE OF ACTIVE HIV-1 RESERVOIRS IS LIMITED TO STUDIES OF CD4+ T-CELLS IN THE PERIPHERAL BLOOD. THE NATURE OF ACTIVE RESERVOIRS IN MYELOID CELLS WITHIN TISSUE COMPARTMENTS HAVE REMAINED LARGELY UNCHARACTERIZED. IN OUR PRELIMINARY STUDIES, WE HAVE SHOWN THAT ALVEOLAR MACROPHAGES (AMS), WHICH ARE THE PREDOMINANT HIV-1-INFECTED CELL-TYPE IN THE LUNG, CONTINUE TO TRANSCRIBE VIRAL RNAS UNDER LONG-TERM CART. WE HAVE ALSO SHOWN THAT, UNLIKE CD4+ T-CELLS, THE LEVELS OF VIRAL RNA-POSITIVE AMS DO NOT DECREASE EVEN AFTER YEARS-LONG THERAPY. IN THIS STUDY, WE PROPOSE TO COMPREHENSIVELY CHARACTERIZE THESE ACTIVE AM RESERVOIRS IN THERAPY-SUPPRESSED INDIVIDUALS BY ADDRESSING THREE SPECIFIC QUESTIONS: (1) HOW THE PROVIRAL LANDSCAPES AND PROFILES OF VIRAL RNA TRANSCRIPTS IN AMS COMPARE BETWEEN CART-NAIVE AND TREATED INDIVIDUALS, (2) HOW DOES THE ONGOING VIRAL TRANSCRIPTION AFFECT IMMUNOLOGICAL FUNCTIONS AND SURVIVAL OF THE ACTIVE MACROPHAGE RESERVOIRS AND (3) DO ACTIVE RESERVOIR MACROPHAGES IMPACT VIRAL REBOUND AND REPLICATION IN THE NEIGHBORING REACTIVATION-CAPABLE AMS AND CD4+ T-CELLS. WE WILL UTILIZE STATE-OF-THE-ART MOLECULAR, CELLULAR AND IMMUNOLOGICAL METHODS AND A WELL- CHARACTERIZED HUMAN SUBJECT COHORT TO EXAMINE THE SPECIFIC AIMS. THE STUDY WILL PROVIDE FUNDAMENTAL SCIENTIFIC KNOWLEDGE ABOUT A NEW LAYER OF COMPLEXITY IN HIV-1 PERSISTENCE AND REVEAL THE BIOLOGICAL SIGNIFICANCE OF ACTIVE AM RESERVOIRS. UNDERSTANDING THE MOLECULAR MECHANISMS OF CONTINUED VIRAL TRANSCRIPTION IN ACTIVE AMS AND ITS ADVERSE CELLULAR EFFECTS WILL HELP IN DEVISING TAILORED STRATEGIES FOR ELIMINATING THESE MYELOID RESERVOIR CELLS.

Posted 5/17/24, 12:00 AM